Research programme: alpha-7 nicotinic acetylcholine receptor modulators - Alpharmagen
Latest Information Update: 15 Jan 2015
At a glance
- Originator Alpharmagen
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Alpha7 nicotinic acetylcholine receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cognition disorders
Most Recent Events
- 15 Jan 2015 Preclinical trials in Cognition disorders in USA (unspecified route)
- 14 Jun 2013 Early research in Cognition disorders in USA (unspecified route)